Curis, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRIS research report →
About the company
Curis, Inc. , a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
- CEO
- James Dentzer
- IPO
- 2000
- Employees
- 24
- HQ
- Lexington, MA, US
Price Chart
- Market Cap
- $4.56M
- P/E
- -0.29
- P/S
- 0.65
- P/B
- 5.28
- EV/EBITDA
- 0.44
- Div Yield
- 0.00%
- Gross Margin
- 99.45%
- Op Margin
- -485.12%
- Net Margin
- -299.66%
- ROE
- 805.67%
- ROIC
- -259.95%
- Revenue
- $9.44M · -13.43%
- Net Income
- $-7,582,000 · 82.53%
- EPS
- $-0.58 · 91.57%
- Op Income
- $-32,902,000
- FCF YoY
- 31.25%
- 52W High
- $2.01
- 52W Low
- $0.18
- 50D MA
- $0.49
- 200D MA
- $0.97
- Beta
- 3.07
- Avg Volume
- 3.27M
Get TickerSpark's AI analysis on CRIS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 26 | KAITIN KENNETH I | buy | 10,000 |
| Mar 20, 26 | Zung Jonathan B. | other | 66,667 |
| Mar 20, 26 | Zung Jonathan B. | other | 50 |
| Mar 20, 26 | Hamdy Ahmed MD | other | 66,667 |
| Mar 20, 26 | Hamdy Ahmed MD | other | 50 |
| Mar 20, 26 | Duvall Diantha | other | 66,666 |
| Mar 20, 26 | Duvall Diantha | other | 50 |
| Mar 20, 26 | Dentzer James E | other | 133,333 |
| Mar 20, 26 | Dentzer James E | other | 100 |
| Mar 20, 26 | Rubin Marc | other | 26,667 |
Our CRIS coverage
Recent articles, reports, and earnings notes.
No research on CRIS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CRIS report →Similar companies
Peers in the same neighborhood.